PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD.
In May and June 2018, Protagenic Therapeutics, Inc. (the “Company”) began discussions with select business development individuals representing large pharmaceutical companies with which the Company seeks to form one or more strategic corporate partnerships.
In connection with these discussions, the Company has created a series of pitch slide decks, describing the advantages of the Company’s lead drug compound, PT00114.
The slide deck furnished hereto as Exhibit 99.1 is a compilation of all such pitch decks used during the months of May and June.
The information in this Form 8-K (including the Exhibit) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referenced in such a filing.
Item 9.01. Financial Statements and Exhibits.
Protagenic Therapeutics, Inc.new Exhibit…To view the full exhibit click here
About PROTAGENIC THERAPEUTICS, INC. (OTCMKTS:PTIX)
Protagenic Therapeutics, Inc., formerly Atrinsic, Inc., is a development-stage company. The Company is a biotechnology company that specializes in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. The Company provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-base, brain active therapeutics. The Company has developed a portfolio of neuropeptides that are in various stages of development and preclinical evaluation for the treatment of various mood disorders. These neuropeptides are called PT00114, PT00121, PT00211, PT00311 and PT00411. As of September 30, 2016, the Company has not generated any revenue.